Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 1/20 | 0.72 |
| ▸ | TRPV1 | Q8NER1 | 16/20 | 0.60 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.58 |
| ▸ | CA1 | P00915 | 2/20 | 0.57 |
| ▸ | CA2 | P00918 | 2/20 | 0.57 |
| ▸ | CA7 | P43166 | 2/20 | 0.57 |
| ▸ | CA9 | Q16790 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5950423 | 0.91 | KDR (0.74) | KDRTRPV1PDK1CA1CA2 | |
| SCHEMBL28901338 | 0.90 | KDR (0.72) | KDRTRPV1PDK1CA1CA2 | |
| SCHEMBL6430968 | 0.89 | KDR (0.70) | KDRTRPV1 | |
| SCHEMBL29494948 | 0.85 | KDR (0.82) | KDRTRPV1PDK1CA1CA2 | |
| SCHEMBL22092657 | 0.85 | KDR (0.82) | KDRTRPV1PDK1CA1CA2 | |
| SCHEMBL6438545 | 0.85 | SLC2A1 (0.72) | CA1CA2CA9 | |
| SCHEMBL118026 | 0.85 | KDR (1.00) | KDRTRPV1PDK1CA1CA2 | |
| SCHEMBL29364392 | 0.85 | KDR (1.00) | KDRTRPV1PDK1CA1CA2 | |
| SCHEMBL12320168 | 0.84 | KDR (0.70) | KDRTRPV1PDK1CA1CA2 | |
| SCHEMBL14714426 | 0.82 | TRPV1 (0.78) | KDRTRPV1CA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050080112-A1 | Compounds for use in disorders associated with mast cell or basophil acitvity | POSEIDON PHARMACEUTICALS A/S (DK) | 2005-04-14 | — | — | US | claimed |
| US-20050080112-A1 | Compounds for use in disorders associated with mast cell or basophil acitvity | POSEIDON PHARMACEUTICALS A/S (DK) | 2005-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080112-A1 | Compounds for use in disorders associated with mast cell or basophil acitvity | CPA3, HNMT, CMA1 | KDR 4778/4885TRPV1 206/4885PDK1 3544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.